Skip to main content

Advertisement

SpringerLink
Log in

Comparative study between intravenous and subcutaneous administration of cladribine in treatment of hairy cell leukemia patients

  • Original Article
  • Published:
Comparative Clinical Pathology Aims and scope Submit manuscript

Abstract

Cladribine is a cytotoxic agent with high activity in hematological malignancies. It is usually administered intravenously. The study was carried out on 20 Egyptian hairy cell leukemia cases; 17 cases were de novo, and 3 cases were relapsed. Four (20%) were treated with IV cladribine, and 16 (80%) were treated with subcutaneous (SC) cladribine. An average duration of response was 36 months with no relapses in cases receiving IV cladribine vs. 25% relapse rate in cases receiving SC cladribine, with no significant difference between them. The subcutaneous administration of cladribine has a positive benefit/risk ratio in the treatment of patients with hairy cell leukemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Anderson KC, Boyd AW, Fisher DC et al (1985a) Hairy cell leukemia: a tumor of pre-plasma cells. Blood 65:620–629

    PubMed  CAS  Google Scholar 

  • Anderson KC, Boyd AW, Fisher DC (1985b) Hairy cell leukemia: a tumor of pre-plasma cells. Blood 65:620–629

    PubMed  CAS  Google Scholar 

  • Baker PK, Pettitt AR, Slupsky JR et al (2002) Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion. Blood 100(2):647–653

    Article  PubMed  CAS  Google Scholar 

  • Berman E, Heller G, Kempin S et al (1990) Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood 75:839–845

    PubMed  CAS  Google Scholar 

  • Burke JS, Byrne GE Jr, Rappaport H (1974) Hairy cell leukemia (leukemic reticuloendotheliosis). I. A clinical pathologic study of 21 patients. Cancer 33:1399

    Article  PubMed  CAS  Google Scholar 

  • Catovsky D (1977) Hairy cell leukemia and prolymphocytic leukemia. Clinical Haematology 6:245–268

    CAS  Google Scholar 

  • Catovsky D, Pettit JE, Galton DAG et al (1974) Leukaemic reticuloendotheliosis (“hairy” cell leukaemia): a distinct clinicopathological entity. Br J Haematol 26:9

    Article  PubMed  CAS  Google Scholar 

  • Cheson BD, Sorensen JM, Venda DA, Montella MJ, Barrett JA, Damasio E (1998) Treatment of hairy cell leukemia with 2 cholorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 16(9):3007–3015

    PubMed  CAS  Google Scholar 

  • DiGiuseppe JA, Borowitz MJ (1998) Clinical utility of flow cytometry in the chronic lymphoid leukemias. Semin Oncol 25:6–10

    PubMed  CAS  Google Scholar 

  • Ellis ED, Moormeier JA, Golomb HM (1990) The treatment of hairy cell leukemia: a review. Leuk Lymphoma 1:77

    Article  Google Scholar 

  • Estey EH, Kurzrock R, Kantarjian HM et al (1992) Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CDA). Blood 79:882–887

    PubMed  CAS  Google Scholar 

  • Golomb HM (1978) Hairy cell leukemia: an unusual lymphoproliferative disease: a study of 24 patients. Cancer 42:946

    Article  PubMed  CAS  Google Scholar 

  • Golomb HM, Fefer A, Golde DW et al (1987) Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia. Semin Oncol 14(Suppl 2):13–17

    PubMed  CAS  Google Scholar 

  • Gotić M, Rolović Z, Radosević N, Draguljac N, Jovanović V, Bogdanović A, Bosković D, [Results of treatment in patients with hairy cell leukemia with splenectomy, alpha-interferon and deoxycoformycin]. Srp Arh Celok Lek. 2000 Jul-Aug;128 (7-8):262–70

    Google Scholar 

  • Grever M, Kopecky K, Foucar MK et al (1995) Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 13(4):974–982

    PubMed  CAS  Google Scholar 

  • Juliusson G, Liliemark J (1992) Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′-deoxyadenosine (CdA): relation to opportunistic infections. Blood 79:888–894

    PubMed  CAS  Google Scholar 

  • Katayama I, Finkel HE (1974) Leukemic reticuloendotheliosis. A clinicopathologic study with review of the literature. Am J Med 57:115

    Article  PubMed  CAS  Google Scholar 

  • Korsmeyer SJ, Greene WC, Cossman J et al (1983) Rearrangement and expression of immunoglobulin of Fac antigen in hairy cell leukemia. Proc Natl Acad Sci USA 80:4522–4526

    Article  PubMed  CAS  Google Scholar 

  • Liliemark J, Albertioni F, Hassan M, Juliusson G (1992) On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 10:1514–1518

    PubMed  CAS  Google Scholar 

  • Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D (2001) The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia 15(1):184–186

    Article  PubMed  CAS  Google Scholar 

  • Piro LD, Carrera CJ, Carson DA, Beutler E (1990) Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N England J Med 322:1117–1121

    Article  CAS  Google Scholar 

  • Piro LD, Saven A, Ellison D et al (1992) Prolonged complete remissions following 2-chlorodeoxyadenosine (2-CDA) in hairy cell leukemia (HCL). Proc Am Soc Clin Oncol 11:259

    Google Scholar 

  • Ratain MJ, Golomb HM, Vardiman JW, Vokes EE, Jacobs RH, Daly K (1985) Treatment of hairy cell leukemia with recombinant alpha 2 interferon. Blood 65(3):644–648

    PubMed  CAS  Google Scholar 

  • Ratain MJ, Golomb HM, Vardiman JW et al (1988) Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables. J Clin Oncol 6:1714–1721

    PubMed  CAS  Google Scholar 

  • Robak T et al (2007) Cladribine in a daily versus a weekly schedule for untreated active hairy cell leukemia. Final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 109(9):3672–3675

    Article  PubMed  CAS  Google Scholar 

  • Robbins BA, Ellison DJ, Spinosa JC et al (1993) Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 82:1277–1287

    PubMed  CAS  Google Scholar 

  • Sainati L, Matutes E, Mulligan S, de Oliveria MP, Rani S, Lampert IA, Catovsky D (1990) "A variant form of hairy cell leukemia, resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients. Blood 76(1):157

    PubMed  CAS  Google Scholar 

  • Saven A et al (1999) Filgratism for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood 93(8):2471–2477

    PubMed  CAS  Google Scholar 

  • Schrek R, Donnelly WJ (1966) Hairy cells in blood in lymphoreticular neoplastic disease and flagellated cells of normal lymph nodes. Blood 27(2):199–211

    PubMed  CAS  Google Scholar 

  • Stewart DJ, Keating MJ (1980) Radiation exposure as a possible etiologic factor in hairy cell leukemia (leukemic reticuloendotheliosis). Cancer 46:1577

    Article  PubMed  CAS  Google Scholar 

  • Tallman MS, Zakarija A (2005) Hairy cell leukemia: survival and relapse. Long-term follow-up of purine analog-based therapy and approach for relapsed disease. Transfus Apher Sci 32(1):99–103

    Article  PubMed  Google Scholar 

  • von Rohr A, Schmitz SF, Tichelli A, Hess U, Piguet D, Wernli M, Frickhofen N, Konwalinka G, Zulian G, Ghielmini M, Rufener B, Racine C, Fey MF, Cerny T, Betticher D, Tobler A, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (2002) Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann Oncol 13(10):1641–1649

    Article  Google Scholar 

  • Westbrook CA, Groopman JE, Golde DW (1984) Hairy cell leukemia: disease pattern and prognosis. Cancer 54:500–506

    Article  PubMed  CAS  Google Scholar 

  • Ya-In C, Brandwein J, Pantalony D, Chang H (2005) Hairy cell leukemia variant with features of intrasinusoidal bone marrow involvement. Arch Pathol Lab Med 129(3):395–398

    PubMed  Google Scholar 

  • Yam LT, Phyliky RL, Li CY (1984) Benign and neoplastic disorders simulating hairy cell leukemia. Semin Oncol 11:353–361

    PubMed  CAS  Google Scholar 

  • Yam LT, Janckila AJ, Li CY, Lam WK (1987) Cytochemistry of tartrate-resistant acid phosphatase: 15 years’ experience. Leukemia 1:285–288

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

None. No funding to declare.

Conflict of interest

All authors have no conflict of interest to report.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Cairo University, Cairo, Egypt

    Nehad M. Tawfik

  2. Haematology Unit, Clinical Pathology Department, Cairo University, Kasr el eini, Cairo, Egypt

    Aml Soliman Nasr

Authors
  1. Nehad M. Tawfik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aml Soliman Nasr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aml Soliman Nasr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tawfik, N.M., Nasr, A.S. Comparative study between intravenous and subcutaneous administration of cladribine in treatment of hairy cell leukemia patients. Comp Clin Pathol 21, 1269–1274 (2012). https://doi.org/10.1007/s00580-011-1277-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00580-011-1277-5

Keywords

Search

Navigation